TBC1D12

Across TCGA pan-cancer cohorts, TBC1D12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBC1D12 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBC1D12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TBC1D12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where TBC1D12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.600	.005	10	view →
GBM	OS	Median	All	0.961	0.821	.002	4	view →
PDAC	OS	Median	All	0.341	0.679	.046	3	view →
LUAD	DFS	Quartile	II,III,IV	0.766	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBC1D12–CCRCC (DFS)

Open the CCRCC breakdown →